Viral vector-mediated RNA interference

被引:105
|
作者
Couto, Linda B. [1 ]
High, Katherine A. [1 ]
机构
[1] Univ Penn Sch Med Director, Howard Hughes Med Inst William H Bennett Prof Ped, Ctr Cellular & Mol Therapeut, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
关键词
SHORT-HAIRPIN RNAS; LONG-TERM INHIBITION; DOUBLE-STRANDED-RNA; MAMMALIAN-CELLS; LENTIVIRAL VECTOR; IN-VIVO; ARTIFICIAL MICRORNAS; STABLE EXPRESSION; TRANSGENIC MICE; MESSENGER-RNAS;
D O I
10.1016/j.coph.2010.06.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNA interference (RNAi) is a powerful gene silencing mechanism that if properly harnessed has the potential to revolutionize medical interventions. Delivery of inhibitory RNAs to target tissues needs to be safe, efficient, and for many diseases, long-lasting, in order to exploit this endogenous mechanism for therapeutic purposes. Viral vector systems, based on adeno-associated viruses and lentiviruses, are ideally suited to mediate RNAi because they can safely transduce a wide range of tissues and provide sustained levels of gene expression. There are now many examples of the use of viral vector-mediated RNAi to inhibit gene expression in animal models of disease, and in many cases proof-of-principle has been demonstrated. The efficient delivery of RNAi has also uncovered a number of concerns that raise questions regarding the clinical application of this technology, including off-target effects, innate immune responses, and alterations in the endogenous microRNA (miRNA) pathway. However, over the past several years, work has been done to address these problems and a number of solutions are now being implemented to mitigate these potential risks. With a deeper understanding of RNAi and continued progress in designing RNAi effectors, viral vector-mediated RNAi has the potential to change the way many diseases are treated.
引用
收藏
页码:534 / 542
页数:9
相关论文
共 50 条
  • [1] Adenovirus vector-mediated doxycycline-inducible RNA interference
    Hosono, T
    Mizuguchi, H
    Katayama, K
    Xu, ZL
    Sakurai, F
    Ishii-Watabe, A
    Kawabata, K
    Yamaguchi, T
    Nakagawa, S
    Mayumi, T
    Hayakawa, T
    [J]. HUMAN GENE THERAPY, 2004, 15 (08) : 813 - 819
  • [2] In vitro inhibition of CSFV replication by retroviral vector-mediated RNA interference
    Li, Jiangnan
    Guo, Huancheng
    Shi, Zixue
    Tu, Changchun
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2010, 169 (02) : 316 - 321
  • [3] Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system
    Erich M Ehlert
    Ruben Eggers
    Simone P Niclou
    Joost Verhaagen
    [J]. BMC Neuroscience, 11
  • [4] Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system
    Ehlert, Erich M.
    Eggers, Ruben
    Niclou, Simone P.
    Verhaagen, Joost
    [J]. BMC NEUROSCIENCE, 2010, 11
  • [5] Adenovirus expression of short hairpin RNA: The road to vector-mediated in vivo RNA interference
    Cautlon, JD
    Clay, CM
    [J]. MOLECULAR THERAPY, 2003, 7 (05) : S305 - S305
  • [6] Viral vector-mediated gene therapies
    Hollinger, Katrin
    Chamberlain, Jeffrey S.
    [J]. CURRENT OPINION IN NEUROLOGY, 2015, 28 (05) : 522 - 527
  • [7] Promoter Compatibility Enables Viral Vector-Mediated Delivery of Antiviral RNA Genes
    Camargo, Carolina
    Lange, Margaret J.
    Burke, Donald H.
    [J]. MOLECULAR THERAPY, 2014, 22 : S285 - S285
  • [8] Viral vector-mediated neuroprotective effects of GDNF in ALS
    不详
    [J]. NEUROSCIENTIST, 2003, 9 (01): : 1 - 1
  • [9] Viral vector-mediated gene therapy for hemophilia B
    Eisensmith, RC
    Woo, SLC
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, 78 (01) : 24 - 30
  • [10] Viral Vector-Mediated Antisense Therapy for Genetic Diseases
    Imbert, Marine
    Dias-Florencio, Gabriella
    Goyenvalle, Aurelie
    [J]. GENES, 2017, 8 (02):